Brusatol has therapeutic efficacy in non-small cell lung cancer by targeting Skp1 to inhibit cancer growth and metastasis
Authors:
- 5 January 2022
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 176, 106059
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanismProceedings of the National Academy of Sciences, 2011
- Mantle cell lymphoma activation enhances bortezomib sensitivityBlood, 2010
- Rictor Forms a Complex with Cullin-1 to Promote SGK1 Ubiquitination and DestructionMolecular Cell, 2010
- The ubiquitous nature of cancer: the role of the SCFFbw7 complex in development and transformationOncogene, 2010
- Preparation, Safety, Pharmacokinetics, and Pharmacodynamics of Liposomes Containing Brucea javanica OilAAPS PharmSciTech, 2010
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene listsNucleic Acids Research, 2008
- Wnt, Hedgehog, and Snail: Sister Pathways That Control by GSK-3beta and beta-Trcp in the Regulation of MetastasisCell Cycle, 2005
- Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complexNature, 2004
- Brusatol-mediated induction of leukemic cell differentiation and G1 arrest is associated with down-regulation of c-mycLeukemia, 2002